Navigenics
Navigenics, Inc. provides DNA tests to consumers. The tests are used to determine risk factors for certain conditions and customers are encouraged to discuss results with their physicians after receiving results. Navigenics offers a $499 plan which tests for disposition to ten of the most common conditions, like breast cancer, diabetes, and heart attacks. The $2499 plan tests for significantly more conditions and provides ongoing access to a genetic consultant who will help the customer understand the results. Navigenics has reportedly received $25 million… more
Recent Contracts
| Price |
Implied Valuation
|
Type | Date |
|---|
Message Board
Log in to SharesPost to view and post messages.
Company Overview
Navigenics, Inc. provides DNA tests to consumers. The tests are used to determine risk factors for certain conditions and customers are encouraged to discuss results with their physicians after receiving results.
Navigenics offers a $499 plan which tests for disposition to ten of the most common conditions, like breast cancer, diabetes, and heart attacks. The $2499 plan tests for significantly more conditions and provides ongoing access to a genetic consultant who will help the customer understand the results.
Navigenics has reportedly received $25 million in funding from Kleiner, Perkins, Caufield & Byers, Sequoia Capital, and Mohr Davidow Ventures.
-
CEO:
Mari Baker
-
HQ:
Foster City, CA
- Capital Raised:
Financings
- Series: B
- Type: Second Round
- Date: November-2007
- Investors:
-
- Kleiner Perkins Caufield & Byers
- Mohr Davidow Ventures
- Sequoia Capital
- Series: A
- Type: First Round
- Date: August-2007
- Investors:
-
- Kleiner Perkins Caufield & Byers
- Sequoia Capital
Round 2
Round 1
Though SharesPost tries to keep this data current and accurate, it may not be either.
You should independently confirm such information prior to a transaction.
News
Documents
Log in to SharesPost to view, download and post Navigenics documents.

